Teva Pharmaceutical Industries Ltd. TEVA had a busy week that included a major debt refinancing, a milestone shift in how its ...

Today marks another meaningful milestone in Teva’s transformation,” said Richard Francis, President and CEO of Teva. “The trading of our ordinary shares on the NYSE is expected to broaden investor ...

CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, ...

Teva Pharmaceutical Industries Ltd. TEVA shares are trading higher after the company announced positive topline results from an ongoing Phase 2a study of TEV ‘408. The study met its primary endpoint.

Teva Pharmaceutical Industries (TEVA) ordinary shares began trading directly on the New York Stock Exchange, completing its transition from its American depositary shares program, the drugmaker said ...

FPS has seen roughly 48,000 options contracts exchanged so far, or 4.2 times the usual intraday volume, with calls accounting ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...

The fund increased its Teva stake, which now accounts for 7.51% of 13F AUM and ranks as its 4th-largest holding. Top holdings after the filing: NYSE:CVS: $617.96 million (13.8% of AUM) NYSE:THC: ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.

Teva Pharmaceutical’s stock has quietly staged a powerful recovery, outpacing broader pharma benchmarks and forcing investors to revisit a name long written off as a value trap. With fresh legal ...